Archive for immunotherapy
Making immunotherapy safe for AML
Acute myeloid leukemia (AML), the second most common leukemia in children, is hard to treat and has a five-year survival rate of just 65 to 70 percent, according to the American Cancer Society. While immunotherapies like monoclonal antibodies or CAR T-cell therapy are effective for certain blood cancers, they have not been possible in AML ... Read More
Nanobodies from alpacas could steer immune attacks on influenza
While conventional flu vaccines are designed to anticipate the influenza strains projected to dominate in the next flu season, they’re only partially effective. And while antiviral drugs are available to treat active flu cases, the body quickly clears them, requiring high, frequent doses. Coupling one existing flu drug with a special ingredient from alpacas, the ... Read More
An unexpected journey reveals a potent way to attack tumors
Research on the effects of prenatal exposure to the Zika virus has yielded an unexpected dividend: a potentially promising way to trigger natural killer (NK) cells to fight cancer. NK cells are first-responder immune cells. When enough of their activating receptors are triggered, they mobilize to kill infected, stressed, or cancerous cells at an early ... Read More
Going out of the box to tackle pancreatic cancer
Pancreatic cancers are deadly and hard to treat, in part because they are so often detected at an advanced stage; overall five-year survival rates are about 11 percent. Two separate labs at Boston Children’s Hospital took out-of-the-box approaches to this difficult cancer, and both uncovered some very promising leads. Wiping out pancreatic tumors’ immune defense ... Read More
Making ready-made CAR T cells for cancer immunotherapy
In CAR T-cell immunotherapy, T cells from a patient’s own blood are engineered to carry so-called chimeric antigen receptors (CAR) that enable the T cells to attack and kill tumor cells. While CAR-T therapy is a powerful approach for certain leukemias and lymphomas, it’s not available for many patients who need it. It can be ... Read More
Immunotherapy for kids: An option for childhood liver cancer?
You may have seen ads for immunotherapy drugs, or even know someone whose cancer has been treated with them. These medications, which use a patient’s own immune system to help fight cancer, are increasingly popular for treating solid tumors in adults. However, immunotherapy has been less successful in treating cancer in kids. The reason for ... Read More
Children with severe MIS-C do better with IVIG and steroids as initial therapy
When children started getting sick with multisystem inflammatory syndrome (MIS-C) in the wake of COVID-19, clinicians largely turned to two treatments. Many used immunoglobulin (IVIG) because of MIS-C’s similarities with Kawasaki disease. And many used steroids such as methylprednisolone because of MIS-C’s inflammatory features. Key takeawayIn this large, rigorous national study, initial treatment of MIS-C ... Read More
Diversifying therapeutic antibodies: From one, come many with potential different uses
A new method for producing antibodies against disease could result in a wider variety of drugs for infectious diseases, immune disease, and even cancer. The immune system naturally produces enormous varieties of antibodies to fight diseases. Therapeutic antibodies — antibodies created against specific therapeutic targets — have been used for decades to either rev up ... Read More
Treating inflammation in MIS-C: An evidence-based approach
Multisystem inflammatory syndrome in children (MIS-C) is a complex, post-COVID-19 spectrum of illness that has affected a small number of children and adolescents. Symptoms can include features of Kawasaki disease, cardiac dysfunction, hypotension and toxic-shock-like signs, abnormal blood coagulation, and prominent GI symptoms. At its core is a hyperinflammatory response that we do not yet ... Read More
Adults with cancer appear more vulnerable to COVID-19
Cancer, particularly metastatic cancer, can be added to the list of medical conditions that pose a significant risk of worse COVID-19 outcomes , suggests a new study. Led by Boston Children’s Hospital and Zhongnan Hospital of Wuhan University, it represents the first large cohort study to examine COVID-19 outcomes in cancer patients. Findings were published ... Read More